1
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Incretin-based therapies: new treatments for type 2 diabetes in the new millennium

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The advent of ‘incretin-based therapies’ – GLP-1 agonists and dipeptidyl-peptidase-4 inhibitors – which result in improvements in glycemic control comparable to those with existing oral hypoglycemic agents, and potentially improve cardiovascular and pancreatic β-cell function, represents a major therapeutic advance in the management of type 2 diabetes. Gastrointestinal adverse effects occur commonly with GLP-1 agonists, and rarely with DPP-4 inhibitors, but are dose-dependent and usually transient. The low risk of hypoglycemia, and beneficial or neutral effects on body weight, render GLP-1 agonists and DPP-4 inhibitors suitable alternatives to insulin secretagogues and insulin in overweight and elderly patients. Incretin-based therapies also improve quality of life in patients with type 2 diabetes, and may be cost-effective in the long term.

          Related collections

          Author and article information

          Journal
          Ther Clin Risk Manag
          Therapeutics and Clinical Risk Management
          Therapeutics and Clinical Risk Management
          Dove Medical Press
          1176-6336
          1178-203X
          2009
          2009
          20 August 2009
          : 5
          : 683-698
          Affiliations
          Discipline of Medicine, Royal Adelaide, Hospital, Adelaide, South Australia, Australia
          Author notes
          Correspondence: Michael Horowitz, Discipline of Medicine, Level 6 Eleanor, Harrald Building, Royal Adelaide Hospital, The University of Adelaide, SA 5005, Australia, Tel +61 (0) 8 8222 5501, Fax +61 (0) 8 8223 3870, Email michael.horowitz@ 123456adelaide.edu.au
          Article
          tcrm-5-683
          2731024
          19707284
          © 2009 Khoo et al, publisher and licensee Dove Medical Press Ltd.

          This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

          Categories
          Review

          Medicine

          dpp-4, therapy, type 2 diabetes, glp-1, incretin

          Comments

          Comment on this article